Evidence for an autoimmune pathogenesis of vitiligo (Q35080073)

6 August 2017

1 reference

title

Evidence for an autoimmune pathogenesis of vitiligo (English)

1 reference

6 August 2017

0 references

1 reference

Katia Ongenae

1

1 reference

PubMed ID

12622785

6 August 2017

Nanny Van Geel

series ordinal

2

1 reference

PubMed ID

12622785

6 August 2017

Jean-Marie Naeyaert

series ordinal

3

1 reference

6 August 2017

1 April 2003

1 reference

Pigment Cell & Melanoma Research

6 August 2017

1 reference

6 August 2017

16

1 reference

6 August 2017

2

1 reference

6 August 2017

90-100

1 reference

Pathophysiology of vitiligo

6 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Autoantibodies and their clinical significance in a black vitiligo population

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Vitiligo in multiple autoimmune syndrome: a retrospective study of 11 cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

The effects of ultraviolet radiation on the human immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Transfer of vitiligo after allogeneic bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Epidermal Changes in Active Vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4+CD45RO+ and CD4+CD25+ of T-helper cells in non-segmental vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Hypothesis: symmetrical cutaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Autoimmune melanocyte destruction in vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

HLA-A2 Restricted, Melanocyte-Specific CD8+ T Lymphocytes Detected in Vitiligo Patients are Related to Disease Activity and are Predominantly Directed Against MelanA/MART1

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Coupling and uncoupling of tumor immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

New Insights into the Pathogenesis of Vitiligo: Imbalance of Epidermal Cytokines at Sites of Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

Vitiligo. Pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoimmune aspects of vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo: where do we stand?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Melanocyte destruction and repopulation in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Review of the etiopathomechanism of vitiligo: a convergence theory

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Subcutaneous sarcoidosis associated with vitiligo, pernicious anaemia and autoimmune thyroiditis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo in diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoimmune thyroid disorders in juvenile chronic arthritis and systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Profile of alopecia areata in Northern India.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo, achlorhydria, and pernicious anaemia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo, rheumatoid arthritis and pernicious anemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

A patient with a seborrheic keratosis which caused impaired hearing by closure of the external auditory meatus.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo in Vogt-Koyanagi-Harada disease: immunohistological analysis of inflammatory site

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Inflammatory vitiligo in Vogt-Koyanagi-Harada disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Frequency and clinical correlates of vitiligo in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Acropigmentation of Dohi in a 12-year-old boy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Psoriasis occurring in amelanotic lesions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo associated with lichen planus. Is there a pathogenetic relationship?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Colocalization of lichen planus and vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases. The French Study Group of Cutaneous Lymphomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoimmunity in vitiligo: relationship with HLA, Gm and Km polymorphisms

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Serum antibodies in vitiligo patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Comparison of the effect of 8-methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Effect of UVB 311 nm irradiation on normal human skin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Mechanisms of ultraviolet (UV) B and UVA phototherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

New and emerging therapies for vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Effect of bursectomy on development of a spontaneous postnatal amelanosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Enhanced integumental and ocular amelanosis following the termination of cyclosporine administration

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Generalized vitiligo after lymphocyte infusion for relapsed leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo-like leucoderma during photochemotherapy for mycosis fungoides

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Detection of Antibodies to Melanocytes in Vitiligo by Specific Immunoprecipitation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoimmune vitiligo: detection of antibodies to melanin-producing cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Detection of antibodies to melanocytes in vitiligo by western immunoblotting

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo autoantibodies are effective against melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Cytolytic antibodies to melanocytes in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Relation Between the Incidence and Level of Pigment Cell Antibodies and Disease Activity in Vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects. II. The IgG and C3 deposits in the skin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Characterization of vitiligo antigens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Identification of pigment cell antigens defined by vitiligo antibodies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Recognition of melanoma cell antigens with antibodies present in sera from patients with vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

The role of tyrosinase in autoimmune vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Tyrosinase as an autoantigen in patients with vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo antibodies are not directed to tyrosinase

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Correlation between vitiligo antibodies and extent of depigmentation in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule-1 expression and an increase in interleukin-8 release by melanocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Peripheral blood lymphocyte imbalance in Koreans with active vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Peripheral T-cell activation in non-segmental vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Nonsegmental vitiligo: decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Circadian rhythm of natural killer cell activity in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

T cell subpopulations in vitiligo: a chronobiologic study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Plasma α-melanocyte-stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

An immunohistological study of cutaneous lymphocytes in vitiligo.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Analysis of the lymphocytic infiltrate in a case of vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Chronic actinic dermatitis with vitiligo-like depigmentation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Serum concentration of the soluble interleukin-2 receptor in vitiligo patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Immunohistochemical studies from vitiligo--comparison between active and inactive lesions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Langerhans cells in various benign and malignant pigment-cell lesions of the skin

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Possible functional impairment of Langerhans' cells in vitiliginous skin. Reduced ability to elicit dinitrochlorobenzene contact sensitivity reaction and decreased stimulatory effect in the allogeneic mixed skin cell lymphocyte culture reaction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Accumulation of identical T cells in melanoma and vitiligo-like leukoderma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Vitiligo: a manifestation of apoptosis?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0749.2003.00023.X

7 January 2021

10.1034/J.1600-0749.2003.00023.X

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12622785